HC Wainwright Reaffirms “Buy” Rating for CalciMedica (NASDAQ:CALC)

HC Wainwright reaffirmed their buy rating on shares of CalciMedica (NASDAQ:CALC) in a report issued on Thursday,Benzinga reports. The firm currently has a $16.00 target price on the stock.

CalciMedica Stock Performance

NASDAQ CALC opened at $3.33 on Thursday. The firm’s fifty day moving average is $4.04 and its two-hundred day moving average is $4.53. CalciMedica has a one year low of $2.68 and a one year high of $8.38. The firm has a market cap of $35.80 million, a PE ratio of -3.08 and a beta of 1.30.

Insider Buying and Selling at CalciMedica

In other news, Director Fred A. Middleton acquired 87,744 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $3.75 per share, with a total value of $329,040.00. Following the purchase, the director now owns 814,300 shares of the company’s stock, valued at $3,053,625. This represents a 12.08 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert N. Wilson acquired 54,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $3.72 per share, with a total value of $200,880.00. Following the transaction, the director now owns 364,196 shares in the company, valued at $1,354,809.12. The trade was a 17.41 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 312,944 shares of company stock valued at $1,172,910 in the last ninety days. Insiders own 41.55% of the company’s stock.

Institutional Trading of CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Atria Investments Inc grew its stake in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the period. Atria Investments Inc owned approximately 0.25% of CalciMedica worth $117,000 at the end of the most recent reporting period.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.